¶¶Òõ¶ÌÊÓƵ

UK Proteostasis Conference

Organisers:
Della David & Oliver Florey (Babraham Institute)
Laura Itzhaki & Ritwick Sawarkar (University of Cambridge).

Confirmed speakers:

• Rick Morimoto (Keynote speaker), Department of Molecular Biosciences, Northwestern University and Royal Society Wolfson Visiting Fellow at the University of Cambridge – The Proteostasis Network as a Biological Clock for Health, Aging and Disease
• Ivana Bjedov, Molecular Biology of Cancer ¶¶Òõ¶ÌÊÓƵ Group, UCL Cancer Institute – Protein phase transitions
• Bernadette Carroll, School of Biochemistry, University of Bristol – Dysregulated proteostasis as a virulence mechanism of pathogenic bacteria, the case of the Mycobacterium ulcerans exotoxin mycolactone
• Pedro Carvalho, Sir William Dunn School of Pathology, University of Oxford – The challenges of predicting amyloidogenicity
• Benedict Cross, PhoreMost, Cambridge – Induced control of protein degradation
• Tuomas Knowles, Department of Chemistry, University of Cambridge – How neuronal signalling connects perception with proteostasis and ageing
• Sheena Radford, Faculty of Biological Sciences, University of Leeds – Diverse ubiquitin chain topologies orchestrate plant immune signalling
• Rahul Samant, Babraham Institute, Cambridge – Deconvoluting cellular proteostasis strategies across proliferative states
• Steven Spoel, Institute of Molecular Plant Sciences, University of Edinburgh – Discovery and development of NXP800: a clinical stage GCN2/ISR activator that inhibits HSF1 transcription for the treatment of ARID1A mutant ovarian cancer
• Rachel Simmonds, Department of Microbial Sciences, University of Surrey – Increased fidelity of protein synthesis extends lifespan
• Rebecca Taylor, School of Biological Sciences, University of East Anglia – title to be confirmed
• Paul Workman, Signal Transduction & Molecular Pharmacology team, Institute of Cancer ¶¶Òõ¶ÌÊÓƵ – Deconvoluting cellular proteostasis strategies across proliferative states

Panel discussion on day 2: How can our knowledge of proteostasis be translated into therapeutic benefit?

Chaired by Kathryn Chapman, Director, Science & Entrepreneurship at Babraham ¶¶Òõ¶ÌÊÓƵ Campus

Panel:

• Paul Thompson, Chief Scientific Officer, Mission Therapeutics
• Fiona Menzies, Associate Vice President, Eli Lilly and Company
• James Hunt, R&D Biologics Engineering, AstraZeneca
• Wei-Li (William) Kuan, Head of Biology of the Alborada Drug Discovery Institute, University of Cambridge
• Ralph Minter, Senior Vice President ¶¶Òõ¶ÌÊÓƵ, Alchemab

See the full programme and register at:

Registration closes on 24th April 2024.

Find out more about the UK Proteostasis Network: